Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) based in Knoxville, TN - is a development stage biopharmaceutical company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional treatments.  

Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis.  Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.com

The Company has ongoing Phase 2 clinical trials at six medical centers:  Sydney Brisbane and Adelaide in Australia; M.D. Anderson in Houston, TX; St. Luke�s Hospital and Health Network in Bethlehem, PA; and California Pacific Medical Center in San Francisco, CA. 

The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology.  Additional information about Provectus is available at http://www.pvct.com/